- Home
- / Alliance Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Alliance Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
£178.8 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 118.2M | 135.6M | 129.8M | 163.2M | 167.4M | 180.7M | 178.8M |
| Cost of goods sold | 42.1M | 47.6M | 45.2M | 52.2M | 64.2M | 74.4M | 68.2M |
| Gross profit | 76.1M | 88.0M | 84.6M | 111.0M | 103.2M | 106.2M | 110.6M |
| Gross profit margin, % | 64.9% | 65.2% | 68.0% | 61.7% | 58.8% | 61.8% | |
| Operating expense total | 44.3M | 50.4M | 47.0M | 73.2M | 63.7M | 55.1M | 72.5M |
| Depreciation and amortization | 7.8M | 2.0M | 21.0M | 16.3M | 57.3M | 89.6M | 46.2M |
| EBITDA | 33.3M | 37.6M | 37.6M | 37.8M | 39.6M | 51.1M | 38.1M |
| EBITDA margin, % | 27.7% | 29.0% | 23.2% | 23.6% | 28.3% | 21.3% | |
| EBIT | 27.5M | 35.6M | 16.3M | 21.6M | (17.7M) | (38.4M) | (6.1M) |
| EBIT margin, % | 26.3% | 12.6% | 13.2% | -10.6% | -21.3% | -3.4% | |
| Interest income | 52.0K | 23.0K | 10.0K | 23.0K | 16.0K | 113.0K | 62.0K |
| Interest expense | 3.5M | 3.8M | 2.7M | 3.6M | 5.4M | 10.0M | 9.2M |
| Pre tax profit | 22.8M | 31.1M | 13.0M | 18.2M | (23.0M) | (48.8M) | (14.5M) |
| Income tax expense | 4.4M | 6.1M | 5.0M | 10.8M | (1.8M) | (15.7M) | (3.7M) |
| Net Income | 18.4M | 25.0M | 8.0M | 7.3M | (21.2M) | (33.1M) | (10.7M) |